for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akers Biosciences Inc

AKER.OQ

Latest Trade

2.96USD

Change

0.02(+0.68%)

Volume

2,055

Today's Range

2.87

 - 

3.00

52 Week Range

2.75

 - 

36.72

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Akers Biosciences Inc Announces One-For-Twenty Four Reverse Stock Split

Nov 22 (Reuters) - Akers Biosciences Inc <AKER.O>::AKERS BIOSCIENCES, INC. ANNOUNCES ONE-FOR-TWENTY FOUR REVERSE STOCK SPLIT.AKERS BIOSCIENCES INC - EFFECTIVE NOV 25, CO WILL EFFECT A REVERSE STOCK SPLIT OF ITS COMMON STOCK.

Akers Biosciences Says Appointed Christopher C. Schreiber As Executive Chairman Of Board

Nov 1 (Reuters) - Akers Biosciences Inc <AKER.O>::AKERS BIOSCIENCES - PROVIDED HOWARD YEATON WITH 60 DAYS NOTICE OF ITS INTENT TO TERMINATE HIM AS CEO, INTERIM CFO .AKERS BIOSCIENCES SAYS ON NOV 1, BOARD APPOINTED CHRISTOPHER C. SCHREIBER, CURRENT DIRECTOR OF CO AS EXECUTIVE CHAIRMAN OF BOARD OF CO.AKERS BIOSCIENCES- INTENTION TO NEGOTIATE ARRANGEMENT WITH YEATON WHEREBY HE WILL CONTINUE TO SERVE PAST SUCH 60 DAY PERIOD IN ROLE OF INTERIM CFO.

Akers Biosciences Inc Files For Mixed Shelf Of Up To $25 Mln

Nov 1 (Reuters) - Akers Biosciences Inc <AKER.O>::AKERS BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $25 MILLION – SEC FILING.

Akers Biosciences Reports Q2 2019 Earnings

Aug 15 (Reuters) - Akers Biosciences Inc <AKER.O>::AKERS BIOSCIENCES REPORTS Q2 2019 EARNINGS.AKERS BIOSCIENCES INC - AT JUNE 30, 2019, CO HAD CASH, RESTRICTED CASH AND MARKETABLE SECURITIES OF $4.39 MILLION.AKERS BIOSCIENCES INC - DIRECTORS' PROCESS REMAINS UNDERWAY TO EVALUATE STRATEGIC ALTERNATIVES.AKERS BIOSCIENCES INC - BOARD HAS BEEN AND WILL CONTINUE TO CONSIDER A RANGE OF POTENTIAL STRATEGIC ALTERNATIVES.

Akers Biosciences Reports Q1 Operating Loss Of $0.9 Mln

May 20 (Reuters) - Akers Biosciences Inc <AKER.O>::AKERS BIOSCIENCES REPORTS Q1 2019 EARNINGS.AKERS BIOSCIENCES INC - BOARD IS CONSIDERING A RANGE OF POTENTIAL STRATEGIC ALTERNATIVES.AKERS BIOSCIENCES INC - AT MARCH 31, 2019, AKERS BIO HAD CASH, RESTRICTED CASH AND MARKETABLE SECURITIES OF $5.23 MILLION..AKERS BIOSCIENCES INC - RECURRING EXPENSES ARE ANTICIPATED TO BE MATERIALLY LOWER THROUGHOUT REMAINDER OF 2019 THAN SAME PERIOD IN 2018.AKERS BIOSCIENCES INC - QTRLY OPERATING LOSS WAS $0.9 MILLION.

Akers Biosciences - Anticipated That Trading In Common Stock On Aim Will Cease, Delisting Will Take Effect, From 7.00 A.M. (Gmt) On March 29

March 5 (Reuters) - Akers Biosciences Inc <AKER.O>::AKERS BIOSCIENCES - ANTICIPATED THAT TRADING IN COMMON STOCK ON AIM WILL CEASE, DELISTING WILL TAKE EFFECT, FROM 7.00 A.M. (GMT) ON MARCH 29.

Akers Biosciences Announces Restoration Of Trading On AIM Market Of LSE

Nov 16 (Reuters) - Akers Biosciences Inc <AKER.O>::AKERS BIOSCIENCES - REVERSE STOCK SPLIT UPDATE.AKERS BIOSCIENCES INC - RESTORATION OF TRADING ON AIM MARKET OF LONDON STOCK EXCHANGE.AKERS BIOSCIENCES - WORKSTREAMS REQUIRED FOR ADMISSION TO AIM MARKET CO'S SHARES AS A RESULT OF REVERSE STOCK SPLIT HAVE NOW BEEN COMPLETED.

Akers Biosciences announces Q3 earnings

Nov 15 (Reuters) - Akers Biosciences Inc <AKER.O>::AKERS BIOSCIENCES ANNOUNCES Q3 2018 EARNINGS.Q3 REVENUE FELL 18 PERCENT TO $557,100.COMPANY CONTINUING TO EVALUATE STRATEGIC ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE.

Akers Biosciences announces intention to explore strategic alternatives to maximize shareholder value

Nov 7 (Reuters) - Akers Biosciences Inc <AKER.O>::AKERS BIOSCIENCES ANNOUNCES INTENTION TO EXPLORE STRATEGIC ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE.AKERS BIOSCIENCES INC - PROCESS WILL CONSIDER A RANGE OF POTENTIAL STRATEGIC ALTERNATIVES INCLUDING BUSINESS COMBINATIONS.AKERS BIOSCIENCES INC - EFFECTING A REVERSE STOCK SPLIT OF ITS ISSUED AND OUTSTANDING COMMON STOCK.AKERS BIOSCIENCES - DOES NOT PLAN TO DISCLOSE OR COMMENT ON DEVELOPMENTS REGARDING STRATEGIC REVIEW PROCESS UNTIL IT IS COMPLETE.AKERS BIOSCIENCES INC - REVERSE STOCK SPLIT STOCK OF 1 SHARE OF COMMON STOCK FOR EVERY 8 SHARES OF COMMON STOCK ON NOV 8, 2018.

Akers Biosciences Appoints Howard R Yeaton as Chief Executive Officer

Oct 8 (Reuters) - Akers Biosciences Inc <AKER.O>::ANNOUNCES A LEADERSHIP CHANGE, STRATEGIC UPDATE, LEGAL SETTLEMENT AND AN AIM UPDATE.SAYS HOWARD R. YEATON HAS BEEN APPOINTED TO POSITION OF CHIEF EXECUTIVE OFFICER EFFECTIVE IMMEDIATELY.SAYS JOHN GORMALLY HAS RESIGNED BOTH AS CHIEF EXECUTIVE OFFICER AND AS A MEMBER OF BOARD OF DIRECTORS OF COMPANY EFFECTIVE IMMEDIATELY.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up